Publication Name	World Journal of Gastroenterology
Manuscript ID	19904
Country	Japan

Received	2015-05-26 10:22
Peer-Review Started	2015-05-27 08:23
To Make the First Decision	2015-08-31 08:30
Return for Revision	2015-09-06 10:59
Revised
Second Decision	2015-11-03 09:04
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-11-19 16:34
Articles in Press	2015-11-19 16:34
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-12-15 21:40
Publish the Manuscript Online	2015-12-31 13:27

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Topic Highlights
Article Title	Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Yukihiro Haruyama and Hiroaki Kataoka
Funding Agency and Grant Number	Funding Agency Grant Number Chugai Pharmaceutical Co. (to Kataoka H) Grant-in-Aid from The Ministry of Education, Culuture, Sports, Science and Technology, Japan 24390099 (to Kataoka H)
Corresponding Author	Hiroaki Kataoka, MD, PhD, Section of Oncopathology and Regenerative Biology, Department of Pathology, Faculty of Medicine, University of Miyazaki, 5200 Kihara, Kiyotake, Miyazaki 889-1692, Japan. mejina@med.miyazaki-u.ac.jp
Key Words	Glypican-3; Enzyme-linked immunosorbent assay; Hepatocellular carcinoma; Prognosis; Companion diagnostics; Immunohistochemistry
Core Tip	Glypican-3 is frequently overexpressed in hepatocellular carcinoma (HCC). Accumulating evidence indicates that high glypican-3 expression is a significant prognostic factor that predicts poor outcome of patients with HCC. Thus, it serves as a promising molecular target for the development of novel therapies for HCC, and preclinical and clinical trials targeting glypican-3 are currently underway. Evaluation of the glypican-3 levels in HCC tissues or in sera of patients with HCC would be of value for predicting the patients’ prognosis and companion diagnostics for future glypican-3-targeting therapies.
Publish Date	2015-12-31 13:27
Citation	Haruyama Y, Kataoka H. Glypican-3 is a prognostic factor and an immunotherapeutic target in hepatocellular carcinoma. World J Gastroenterol 2016; 22(1): 275-283
URL	http://www.wjgnet.com/1007-9327/full/v22/i1/275.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i1.275

Full Article (PDF)	WJG-22-275.pdf
Full Article (Word)	WJG-22-275.doc
Manuscript File	19904-Review.docx
Answering Reviewers	19904-Answering reviewers.pdf
Audio Core Tip	19904-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	19904-Conflict-of-interest statement.pdf
Copyright License Agreement	19904-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	19904-Language certificate.pdf
Peer-review Report	19904-Peer-review(s).pdf
Scientific Misconduct Check	19904-Scientific misconduct check.pdf
Scientific Editor Work List	19904-Scientific editor work list.pdf